Artwork

Indhold leveret af OncoPharmPod and John Bossaer. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af OncoPharmPod and John Bossaer eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

HOPA '24, Site Agnositc T-DXd, & ALINA

14:10
 
Del
 

Manage episode 412036875 series 1848091
Indhold leveret af OncoPharmPod and John Bossaer. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af OncoPharmPod and John Bossaer eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
What I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma. Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2 amplified solid tumors. Finally, the ALINA study, adjuvant alectinib in ALK+ NSCLC, was published in this week's NEJM.
  continue reading

351 episoder

Artwork

HOPA '24, Site Agnositc T-DXd, & ALINA

OncoPharm

59 subscribers

published

iconDel
 
Manage episode 412036875 series 1848091
Indhold leveret af OncoPharmPod and John Bossaer. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af OncoPharmPod and John Bossaer eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
What I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma. Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2 amplified solid tumors. Finally, the ALINA study, adjuvant alectinib in ALK+ NSCLC, was published in this week's NEJM.
  continue reading

351 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning